Epigenetics in kidney diseases.

2区 医学 Q1 Chemistry
Advances in Clinical Chemistry Pub Date : 2021-01-01 Epub Date: 2020-10-21 DOI:10.1016/bs.acc.2020.09.005
Hao Ding, Lu Zhang, Qian Yang, Xiaoqin Zhang, Xiaogang Li
{"title":"Epigenetics in kidney diseases.","authors":"Hao Ding,&nbsp;Lu Zhang,&nbsp;Qian Yang,&nbsp;Xiaoqin Zhang,&nbsp;Xiaogang Li","doi":"10.1016/bs.acc.2020.09.005","DOIUrl":null,"url":null,"abstract":"<p><p>Epigenetics examines heritable changes in DNA and its associated proteins except mutations in gene sequence. Epigenetic regulation plays fundamental roles in kidney cell biology through the action of DNA methylation, chromatin modification via epigenetic regulators and non-coding RNA species. Kidney diseases, including acute kidney injury, chronic kidney disease, diabetic kidney disease and renal fibrosis are multistep processes associated with numerous molecular alterations even in individual kidney cells. Epigenetic alterations, including anomalous DNA methylation, aberrant histone alterations and changes of microRNA expression all contribute to kidney pathogenesis. These changes alter the genome-wide epigenetic signatures and disrupt essential pathways that protect renal cells from uncontrolled growth, apoptosis and development of other renal associated syndromes. Molecular changes impact cellular function within kidney cells and its microenvironment to drive and maintain disease phenotype. In this chapter, we briefly summarize epigenetic mechanisms in four kidney diseases including acute kidney injury, chronic kidney disease, diabetic kidney disease and renal fibrosis. We primarily focus on current knowledge about the genome-wide profiling of DNA methylation and histone modification, and epigenetic regulation on specific gene(s) in the pathophysiology of these diseases and the translational potential of identifying new biomarkers and treatment for prevention and therapy. Incorporating epigenomic testing into clinical research is essential to elucidate novel epigenetic biomarkers and develop precision medicine using emerging therapies.</p>","PeriodicalId":50872,"journal":{"name":"Advances in Clinical Chemistry","volume":" ","pages":"233-297"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.acc.2020.09.005","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Clinical Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/bs.acc.2020.09.005","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/10/21 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Chemistry","Score":null,"Total":0}
引用次数: 8

Abstract

Epigenetics examines heritable changes in DNA and its associated proteins except mutations in gene sequence. Epigenetic regulation plays fundamental roles in kidney cell biology through the action of DNA methylation, chromatin modification via epigenetic regulators and non-coding RNA species. Kidney diseases, including acute kidney injury, chronic kidney disease, diabetic kidney disease and renal fibrosis are multistep processes associated with numerous molecular alterations even in individual kidney cells. Epigenetic alterations, including anomalous DNA methylation, aberrant histone alterations and changes of microRNA expression all contribute to kidney pathogenesis. These changes alter the genome-wide epigenetic signatures and disrupt essential pathways that protect renal cells from uncontrolled growth, apoptosis and development of other renal associated syndromes. Molecular changes impact cellular function within kidney cells and its microenvironment to drive and maintain disease phenotype. In this chapter, we briefly summarize epigenetic mechanisms in four kidney diseases including acute kidney injury, chronic kidney disease, diabetic kidney disease and renal fibrosis. We primarily focus on current knowledge about the genome-wide profiling of DNA methylation and histone modification, and epigenetic regulation on specific gene(s) in the pathophysiology of these diseases and the translational potential of identifying new biomarkers and treatment for prevention and therapy. Incorporating epigenomic testing into clinical research is essential to elucidate novel epigenetic biomarkers and develop precision medicine using emerging therapies.

肾脏疾病的表观遗传学。
表观遗传学检查DNA及其相关蛋白的可遗传变化,基因序列突变除外。表观遗传调控通过表观遗传调控因子和非编码RNA物种的DNA甲基化、染色质修饰等作用在肾细胞生物学中发挥着重要作用。肾脏疾病,包括急性肾损伤、慢性肾病、糖尿病肾病和肾纤维化,是一个多步骤的过程,甚至在单个肾细胞中也有许多分子改变。表观遗传改变,包括异常的DNA甲基化,异常的组蛋白改变和microRNA表达的变化都有助于肾脏的发病。这些变化改变了全基因组的表观遗传特征,破坏了保护肾细胞免受不受控制的生长、凋亡和其他肾脏相关综合征发展的重要途径。分子变化影响肾细胞及其微环境的细胞功能,驱动和维持疾病表型。本文就急性肾损伤、慢性肾病、糖尿病肾病和肾纤维化四种肾脏疾病的表观遗传机制作一综述。我们主要关注DNA甲基化和组蛋白修饰的全基因组图谱,以及这些疾病病理生理中特定基因的表观遗传调控,以及识别新的生物标志物和预防和治疗方法的转化潜力。将表观基因组检测纳入临床研究对于阐明新的表观遗传生物标志物和利用新兴疗法开发精准医学至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Advances in Clinical Chemistry
Advances in Clinical Chemistry 医学-医学实验技术
CiteScore
10.60
自引率
0.00%
发文量
53
审稿时长
>12 weeks
期刊介绍: Advances in Clinical Chemistry volumes contain material by leading experts in academia and clinical laboratory science. The reviews cover a wide variety of clinical chemistry disciplines including clinical biomarker exploration, cutting edge microarray technology, proteomics and genomics. It is an indispensable resource and practical guide for practitioners of clinical chemistry, molecular diagnostics, pathology, and clinical laboratory sciences in general.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信